Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 65
- Registration Number
- NCT04551495
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇫🇷Institut Bergonié, Bordeaux, France
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 80
- Registration Number
- NCT04536467
- Locations
- 🇪🇬
Beni Suef university, Fayoum, Mesala, Egypt
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1068
- Registration Number
- NCT04478266
- Locations
- 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸Investigational Site Number :8400013, Westwood, Kansas, United States
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 30
- Registration Number
- NCT04072900
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT03860987
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT03839823
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT03822468
- Locations
- 🇺🇸
Southern Cancer Center PC, Mobile, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT03671330
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.